Multifocal Motor Neuropathy News and Research

RSS
Chronic inflammatory demyelinating polyneuropathy commonly misdiagnosed

Chronic inflammatory demyelinating polyneuropathy commonly misdiagnosed

FDA approves Baxter's GAMMAGARD LIQUID for multifocal motor neuropathy

FDA approves Baxter's GAMMAGARD LIQUID for multifocal motor neuropathy

Intravenous immune globulin effective treatment for GBS, CIDP

Intravenous immune globulin effective treatment for GBS, CIDP

Baxter submits GAMMAGARD LIQUID sBLA to FDA for treatment of MMN

Baxter submits GAMMAGARD LIQUID sBLA to FDA for treatment of MMN

Baxter net income increases 15% to $615 million for second quarter 2011

Baxter net income increases 15% to $615 million for second quarter 2011

EMA CHMP issues positive opinion for Baxter's IVIG therapy for multifocal motor neuropathy

EMA CHMP issues positive opinion for Baxter's IVIG therapy for multifocal motor neuropathy

Baxter third quarter net income increases 12% to $595 million

Baxter third quarter net income increases 12% to $595 million

Phase II GAMMAGARD clinical study for Alzheimer's disease: 18-month results announced

Phase II GAMMAGARD clinical study for Alzheimer's disease: 18-month results announced